Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
1994-12-27
|
pubmed:abstractText |
The mortality of premenopausal women with cervical carcinoma has increased in recent decades despite attempts to provide screening. The urinary concentration of the beta core fragment of hCG has been proposed as a sensitive marker in gynecological malignancies, although most studies have not corrected for urine concentration. We measured the urinary concentration of beta core and creatinine in 61 women who developed cervical cancer premenopausally and expressed the concentration of beta core per millimole of creatinine using the 90th percentile of a control group as a cutoff level. While correcting for urinary concentration results in a reduction in sensitivity of the test (67 to 51%), there is improved correlation with prognosis in that after 18 months 81% of women positive for beta core had died, while 80% of women negative for beta core were still alive. Of those initially presenting and dying there was an increase with increasing stage of disease. For patients with initial presentation disease, 11 (79%) of the 14 patients with elevated levels had died compared with 1 of 21 (5%) who were negative for beta core. Urinary beta core fragment may have a major role as a prognostic indicator in cervical carcinoma rather than as a screening or diagnostic marker and enables identification of patients at higher risk of an aggressive disease.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Chorionic Gonadotropin,
http://linkedlifedata.com/resource/pubmed/chemical/Chorionic Gonadotropin, beta...,
http://linkedlifedata.com/resource/pubmed/chemical/Creatinine,
http://linkedlifedata.com/resource/pubmed/chemical/Peptide Fragments,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological
|
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
0090-8258
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
55
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
271-6
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:7525427-Chorionic Gonadotropin,
pubmed-meshheading:7525427-Chorionic Gonadotropin, beta Subunit, Human,
pubmed-meshheading:7525427-Creatinine,
pubmed-meshheading:7525427-Disease Progression,
pubmed-meshheading:7525427-Female,
pubmed-meshheading:7525427-Humans,
pubmed-meshheading:7525427-Neoplasm Staging,
pubmed-meshheading:7525427-Peptide Fragments,
pubmed-meshheading:7525427-Postmenopause,
pubmed-meshheading:7525427-Premenopause,
pubmed-meshheading:7525427-Prognosis,
pubmed-meshheading:7525427-Tumor Markers, Biological,
pubmed-meshheading:7525427-Uterine Cervical Neoplasms
|
pubmed:year |
1994
|
pubmed:articleTitle |
The prognostic significance of urinary beta core fragment in premenopausal women with carcinoma of the cervix.
|
pubmed:affiliation |
Williamson Laboratory for Molecular Oncology, Medical College, St. Bartholomew's Hospital (University of London), West Smithfield, United Kingdom.
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|